SCHEMBL10105334

SCHEMBL10105334

C=C1C=Cc2ccccc2N1C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.42
KMT2A Q03164 4/20 0.42
MEN1 O00255 3/20 0.42
NPSR1 Q6W5P4 3/20 0.42
LMNA P02545 2/20 0.42
THRB P10828 1/20 0.42
P2RX4 Q99571 8/20 0.40
SMN1; SMN2 Q16637 4/20 0.40
GAA P10253 1/20 0.40
MAPK1 P28482 3/20 0.39
TSHR P16473 1/20 0.39
SCN4A P35499 1/20 0.39
SCN5A Q14524 1/20 0.39
SCN9A Q15858 1/20 0.39
P2RX1 P51575 3/20 0.39
P2RX3 P56373 3/20 0.39
P2RX7 Q99572 2/20 0.39
MTNR1A P48039 2/20 0.39
MTNR1B P49286 2/20 0.39
NPC1 O15118 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2607158 0.84 MAPT (0.49) MAPTKMT2AMEN1NPSR1LMNA
SCHEMBL10086947 0.75 MAPT (0.54) MAPTKMT2AMEN1NPSR1LMNA
SCHEMBL18136099 0.74 P2RX4 (0.44) MAPTKMT2AMEN1NPSR1LMNA
SCHEMBL21507788 0.74 MAPT (0.40) MAPTKMT2AMEN1NPSR1LMNA
SCHEMBL10064684 0.74 P2RX4 (0.43) MAPTKMT2AMEN1NPSR1LMNA
SCHEMBL23240871 0.72 MGLL (0.48) MAPTKMT2AMEN1LMNAP2RX4
SCHEMBL18926940 0.72 P2RX4 (0.44) MAPTKMT2AMEN1NPSR1P2RX4
SCHEMBL10449116 0.71 CES1 (0.48) MAPTKMT2AMEN1MAPK1MTNR1A
SCHEMBL6095161 0.71 MAOA (0.44) MAPTKMT2AMEN1NPSR1LMNA
SCHEMBL14804047 0.70 NR1H3 (0.42) LMNAGAAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022004889-A1 INFRARED BLOCKING FILTER, FILTER FOR SOLID-STATE IMAGING ELEMENT, SOLID-STATE IMAGING ELEMENT, AND METHOD FOR PRODUCING FILTER FOR SOLID-STATE IMAGING ELEMENT 凸版印刷株式会社 2022-01-06 WO disclosed
WO-2021145456-A1 INFRARED BLOCKING FILTER, FILTER FOR SOLID-STATE IMAGING ELEMENT, SOLID-STATE IMAGING ELEMENT, AND METHOD FOR PRODUCING FILTER FOR SOLID-STATE IMAGING ELEMENT 凸版印刷株式会社 2021-07-22 WO disclosed
US-9881745-B2 Dye sensitized solar cell ADEKA CORPORATION (JP) 2018-01-30 US disclosed
US-20170267717-A1 Novel method for the production of 18F-labeled active esters and their application exemplified by the preparation of a PSMA-specific PET-tracer MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V. (DE) 2017-09-21 US disclosed
US-20170216332-A1 SMALL MOLECULE ANTI-SCARRING AGENTS UNIVERSITY OF ROCHESTER (US) 2017-08-03 US disclosed
US-9604490-B2 Color laser marking AGFA-GEVAERT (BE) 2017-03-28 US disclosed
US-20160148758-A1 DYE SENSITIZED SOLAR CELL ADEKA CORPORATION (JP) 2016-05-26 US disclosed
US-9239408-B2 Colored photosensitive composition ADEKA CORPORATION (JP) 2016-01-19 US disclosed
US-9110350-B2 Color conversion filter ADEKA CORPORATION (JP) 2015-08-18 US disclosed
US-20130306920-A1 COLORED PHOTOSENSITIVE COMPOSITION ADEKA CORPORATION (JP) 2013-11-21 US disclosed
US-20130237539-A1 Compounds and Compositions for Treating Cancer THE GENERAL HOSPITAL CORPORATION (US) 2013-09-12 US disclosed
US-20130203757-A1 Compounds And Compositions For Treating Cancer THE GENERAL HOSPITAL CORPORATION (US) 2013-08-08 US disclosed
US-20130147345-A1 COLOR CONVERSION FILTER ADEKA CORPORATION (JP) 2013-06-13 US disclosed
EP-2010494-B1 SPECIFIC MONOCATIONIC MONOCHROMOPHORIC COMPOUNDS OF HYDRAZONE TYPE COMPRISING A 2-, 4-PYRIDINIUM OR 2-, 4-QUINOLINIUM UNIT, SYNTHESIS THEREOF, DYE COMPOSITIONS CONTAINING THEM, AND METHOD FOR DYEING KERATIN FIBRES OREAL (FR) 2012-02-01 EP disclosed
US-8012220-B2 Specific monocationic monochromophoric compounds of hydrazone type comprising a 2-, 4-pyridinium or 2-, 4-quinolinium unit, synthesis thereof, dye compositions containing them, and method for dyeing keratin fibres L'OREAL S.A. (FR) 2011-09-06 US disclosed
US-8012220-B2 Specific monocationic monochromophoric compounds of hydrazone type comprising a 2-, 4-pyridinium or 2-, 4-quinolinium unit, synthesis thereof, dye compositions containing them, and method for dyeing keratin fibres L'OREAL S.A. (FR) 2011-09-06 US disclosed
US-20090300856-A1 SPECIFIC MONOCATIONIC MONOCHROMOPHORIC COMPOUNDS OF HYDRAZONE TYPE COMPRISING A 2-, 4-PYRIDINIUM OR 2-, 4-QUINOLINIUM UNIT, SYNTHESIS THEREOF, DYE COMPOSITIONS CONTAINING THEM, AND METHOD FOR DYEING KERATIN FIBRES L'OREAL S.A. (FR) 2009-12-10 US disclosed
US-20090300856-A1 SPECIFIC MONOCATIONIC MONOCHROMOPHORIC COMPOUNDS OF HYDRAZONE TYPE COMPRISING A 2-, 4-PYRIDINIUM OR 2-, 4-QUINOLINIUM UNIT, SYNTHESIS THEREOF, DYE COMPOSITIONS CONTAINING THEM, AND METHOD FOR DYEING KERATIN FIBRES L'OREAL S.A. (FR) 2009-12-10 US disclosed
WO-2007125238-A1 SPECIFIC MONOCATIONIC MONOCHROMOPHORIC COMPOUNDS OF HYDRAZONE TYPE COMPRISING A 2-, 4-PYRIDINIUM OR 2-, 4-QUINOLINIUM UNIT, SYNTHESIS THEREOF, DYE COMPOSITIONS CONTAINING THEM, AND METHOD FOR DYEING KERATIN FIBRES L'ORÉAL (FR) 2007-11-08 WO disclosed
EP-0892411-B1 Methine dye sensitized semiconductor particle FUJIFILM CORP (JP) 2007-09-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090300856-A1 SPECIFIC MONOCATIONIC MONOCHROMOPHORIC COMPOUNDS OF HYDRAZONE TYPE COMPRISING A 2-, 4-PYRIDINIUM OR 2-, 4-QUINOLINIUM UNIT, SYNTHESIS THEREOF, DYE COMPOSITIONS CONTAINING THEM, AND METHOD FOR DYEING KERATIN FIBRES KRT18, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, H1-5 MAPT 2118/4885KMT2A 732/4885MEN1 2261/4885
US-20170216332-A1 SMALL MOLECULE ANTI-SCARRING AGENTS COLGALT1, MMP1, FIBP MAPT 4802/4885KMT2A 3498/4885MEN1 4453/4885
US-20170267717-A1 Novel method for the production of 18F-labeled active esters and their application exemplified by the preparation of a PSMA-specific PET-tracer FGB, F13B, FAP MAPT 1644/4885KMT2A 2206/4885MEN1 288/4885
US-20130203757-A1 Compounds And Compositions For Treating Cancer NQO1, HCCS, TXNRD2 MAPT 2852/4885KMT2A 2855/4885MEN1 2046/4885
US-20130237539-A1 Compounds and Compositions for Treating Cancer NQO1, HCCS, TXNRD2 MAPT 2852/4885KMT2A 2855/4885MEN1 2046/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.